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Abstract 
Background: Hypoxic hepatitis (HH) is a type of acute hepatic injury that is histologically characterized by centri-
lobular liver cell necrosis and that is caused by insufficient oxygen delivery to the hepatocytes. Typical for HH is the 
sudden and significant increase of aspartate aminotransferase (AST) in response to cardiac, circulatory or respiratory 
failure. The aim of this study is to investigate its epidemiology, causes, evolution and outcome.
Methods: The screened population consisted of all adults admitted to the intensive care unit (ICU) at the Ghent Uni-
versity Hospital between January 1, 2007 and September 21, 2015. HH was defined as peak AST > 5 times the upper 
limit of normal (ULN) after exclusion of other causes of liver injury. Thirty-five variables were retrospectively collected 
and used in descriptive analysis, time series plots and Kaplan–Meier survival curves with multi-group log-rank tests.
Results: HH was observed in 4.0% of the ICU admissions at our center. The study cohort comprised 1116 patients. 
Causes of HH were cardiac failure (49.1%), septic shock (29.8%), hypovolemic shock (9.4%), acute respiratory failure 
(6.4%), acute on chronic respiratory failure (3.3%), pulmonary embolism (1.4%) and hyperthermia (0.5%). The 28-day 
mortality associated with HH was 45.0%. Mortality rates differed significantly (P = 0.007) among the causes, ranging 
from 33.3% in the hyperthermia subgroup to 52.9 and 56.2% in the septic shock and pulmonary embolism subgroups, 
respectively. The magnitude of AST increase was also significantly correlated (P < 0.001) with mortality: 33.2, 44.4 and 
55.4% for peak AST 5–10× ULN, 10–20× ULN and > 20× ULN, respectively.
Conclusion: This study surpasses by far the largest cohort of critically ill patients with HH. HH is more common than 
previously thought with an ICU incidence of 4.0%, and it is associated with a high all-cause mortality of 45.0% at 
28 days. The main causes of HH are cardiac failure and septic shock, which include more than 3/4 of all episodes. Clini-
cians should search actively for any underlying hemodynamic or respiratory instability even in patients with moder-
ately increased AST levels.
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Background
Hypoxic hepatitis (HH), also referred to as “ischemic 
hepatitis” or “shock liver,” is a type of acute hepatic injury 
that is histologically characterized by centrilobular liver 
cell necrosis and that is caused by insufficient oxygen 
delivery to the hepatocytes [1]. Typical for this form of 
liver cell necrosis is the sudden and significant increase 
of aspartate aminotransferase (AST) in response to car-
diac, circulatory or respiratory failure [1]. Although often 
missed, HH is a fairly common cause of hepatic dys-
function in an intensive care unit (ICU) with a pooled 
incidence of 2.5% from a recent meta-analysis of 1782 
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patients [2]. Its incidence varies widely among published 
studies, ranging from 0.16 to 12%, depending upon insti-
tution, population studied and definition used [1–8]. 
However, a high associated mortality of approximately 
50% has been consistently observed in all studies [2–6, 8].
The major causes of HH are septic shock, respiratory 
failure and cardiogenic shock [1, 2]. Possible patho-
physiological mechanisms include (1) ischemia due to 
reduced blood supply (forward failure) or due to right 
heart failure (backward failure) with venous congestion, 
(2) hypoxemia due to reduced blood oxygenation and (3) 
increased oxygen consumption due to elevated metabolic 
demand (e.g., in severe hyperthermia or septic shock) [1, 
9]. Patients with comorbidities are more likely to develop 
HH, as they have an increased vulnerability even to 
minor hemodynamic or respiratory insults, such as short 
periods of hypotension or hypoxemia. These comorbidi-
ties contribute substantially to the high mortality associ-
ated with HH [4, 7, 8].
HH is reflected by a typical pattern of liver enzyme 
alterations. It presents with a sudden and significant 
increase of AST, alanine aminotransferase (ALT) and 
lactate dehydrogenase (LDH), reaching their peak lev-
els around 24  h after ICU admission [4] and declining 
steadily to baseline within 10–15 days [1]. Initially, AST 
exceeds ALT, but as ALT declines more slowly, a rever-
sal of the AST/ALT ratio is observed within 3 days after 
the peak [5, 6, 8, 10]. Although this biochemical pattern 
is highly suggestive of HH, it is not pathognomonic and 
warrants further evaluation [1]. Other common causes of 
significant increases in aminotransferase levels are drug-
induced liver injury (e.g., acetaminophen toxicity) and 
acute viral hepatitis. However, studies have shown that a 
sudden and significant increase of AST is caused by HH 
in more than 50% of the cases [11, 12]. Furthermore, HH 
is frequently associated with a prolonged prothrombin 
time and accompanied by additional evidence of end-
organ hypoperfusion, such as impaired renal function 
and increased lactate level [3–6]. A rapid rise and subse-
quent fall in aminotransferase levels with reversal of the 
initial AST/ALT ratio, a prolongation of prothrombin 
time and an increase in serum creatinine level comprise 
a triad of biochemical abnormalities that can suggest the 
diagnosis of HH, as proposed by Raurich et al. [6].
Currently, only limited data from small retrospective 
studies are available, making HH an understudied dis-
ease. The largest cohort described to date was recently 
published and included 565 patients [8]. The aim of this 
study is to investigate in detail the epidemiology, causes, 
evolution and outcome of HH in a large single-center 
cohort. More insight in HH may improve awareness and 
facilitate earlier diagnosis.
Methods
Study cohort and data collection
The screened population consisted of all consecutive 
adults (≥  18  years, n  =  29,874) who were admitted to 
the surgical, cardiac or medical ICU at the Ghent Uni-
versity Hospital between January 1, 2007 and September 
21, 2015. HH was defined as a significant but transient 
increase in AST level above 5 times the upper limit of 
normal (ULN) after exclusion of other potential causes of 
liver injury. Different AST cutoff values for defining HH 
are used in the literature [2]. As HH has been histologi-
cally proven to occur even in patients with moderately 
elevated AST levels (at AST levels of 252 and 300  IU/L 
in the cohort of Cohen et al. [13] and Bynum et al. [14], 
respectively), a cutoff of at least 5 times the ULN was 
used in this study, i.e., 155 and 185 U/L for females and 
males, respectively. The 4012 identified patients whose 
AST level exceeded our cutoff value were evaluated for 
the presence of HH by three independent experts based 
on the pattern of liver enzyme alterations, the daily clini-
cal notes and the discharge summaries. The sine qua non 
was the exposure to a hemodynamic or respiratory insult 
preceding the AST increase and the exclusion of other 
potential causes of liver injury. A flow diagram of the 
exclusion criteria is shown in Fig.  1. Reasons for exclu-
sion were (1) acute liver failure, (2) chronic liver failure, 
(3) other conditions associated with abnormal liver tests 
such as cholangitis and pancreatitis, (4) liver surgery, (5) 
surgery near the liver, (6) hepatic vessel injury or throm-
bosis, (7) rhabdomyolysis, (8) an unclear increase of 
creatine kinase (CK), (9) post-anesthesia without overt 
evidence of an acute cardiac or respiratory event perio-
peratively, (10) missing data and (11) duplicate patients. 
(In patients having developed multiple episodes of HH 
during the study period, only the first episode is eligi-
ble for analysis.) Rhabdomyolysis was defined as serum 
CK exceeding 5 times the ULN (i.e., 850 and 974 U/L 
for females and males, respectively) with a CK-MB/CK 
ratio below 6% [6]. Patients with elevated CK levels but 
with unknown CK-MB value were excluded due to the 
uncertain CK increase. This study was approved by the 
Ethics Committee of the Ghent University Hospital (pro-
ject numbers 2015/0796-0797). Due to the retrospective 
nature of this study, the need for informed consent was 
waived.
Routinely available biochemical parameters were 
recorded, including AST (U/L), ALT (U/L), LDH (U/L), 
bilirubin (mg/dL), alkaline phosphatase (AP) (U/L), 
gamma-glutamyl transpeptidase (U/L), lipase (U/L), 
international normalized ratio (INR), platelet count  (103/
µL), white blood cell count  (103/µL), hemoglobin (g/dL), 
CK (U/L), creatinine (mg/dL), urea (mg/dL) and lactate 
(mg/dL). Values at specific time points were estimated 
Page 3 of 13Van den broecke et al. Ann. Intensive Care  (2018) 8:15 
Fig. 1 Flow diagram of the exclusion criteria. AFLP acute fatty liver of pregnancy, AST aspartate aminotransferase, CK creatine kinase, e.c.i e causa 
ignota, HELLP hemolysis, elevated liver enzymes and low platelet count, HH hypoxic hepatitis, HIPEC hyperthermic intraperitioneal chemotherapy, 
ICU intensive care unit
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using linear interpolation between consecutive recorded 
values. Parameters related to patient characteristics 
included sex, age, body mass index (BMI) and comor-
bidities (diabetes mellitus, cardiac function and chronic 
respiratory disease). Parameters related to the episode 
of HH included cause, severity of illness scores [acute 
physiology II score (APS-II) and the simplified acute 
physiology II score (SAPS-II)], supportive therapy (ino-
tropic agents, vasopressor agents, mechanical ventilation, 
intra-aortic balloon pump (IABP) and need for dialysis), 
ICU and hospital length of stay, duration of the HH epi-
sode, and ICU and in-hospital mortality at 28 days. The 
peak of HH was defined as the point in time (T-ASTmax) 
when AST reached its peak value (ASTmax). In this 
study, the time origin was set to T-ASTmax (designated 
as time 0) and all recorded values are expressed in time 
relative to T-ASTmax for optimal comparison. Severity 
of illness scores were recorded over a time span of 24 h 
around T-ASTmax. Three categories for severity of HH 
were used: “5–10× ULN”, “10–20× ULN” and “>  20× 
ULN”. Seven underlying causes of HH were defined: car-
diac failure, septic shock, hypovolemic shock, pulmonary 
embolism, acute respiratory failure, acute on chronic res-
piratory failure and hyperthermia.
Statistical analysis
Categorical data are reported as counts and percentages. 
Continuous data are reported as the median with the 
first (Q1) and third (Q3) quartiles.  For categorical vari-
ables, comparisons between groups are performed using 
the Pearson’s Chi square test for contingency. For contin-
uous variables, a permutation test based on difference in 
medians between groups is used. A Tukey-like approach 
with  permutation resampling is applied  to adjust P val-
ues for multiple pairwise comparisons. All statistical tests 
are performed as two-sided tests at a significance level of 
0.05. The time trend of laboratory variables is graphically 
assessed using time series plots and stacked bar charts. 
Kaplan–Meier survival curves until 28 days after T-AST-
max and multi-group log-rank tests are used to compare 
the all-cause mortality between groups. Statistical analy-
sis is performed using R version 3.3.2 [15].
Results
Patient and episode characteristics
During the study period, 29,874 adult patients with a 
male-to-female ratio of approximately 3:2 were admit-
ted to the ICU at our center, of whom 4012 patients had 
peak AST levels exceeding 5 times the ULN. In 30.0% 
(1202/4012) of the cases, the elevation of AST was 
caused by HH, resulting in an overall ICU incidence of 
4.0% (1202/29,874). As only the first episode was eligi-
ble for analysis in patients with multiple episodes of HH 
during the study period, the final study cohort comprised 
1116 patients.
The all-cause mortality of patients admitted to the 
ICU at our center during the study period was 7.7% 
(2302/29,874). Among these non-survivors, 19.8% 
(455/2302) had developed HH during their ICU stay. 
The all-cause mortality associated with HH was 45.0% 
(502/1116) at 28  days, of which 90.6% occurred during 
ICU stay. The survival curves by cause of HH are pre-
sented in Fig. 2.
In our study cohort, the median age was 66.0 (Q1–Q3 
55.0–74.0) years with a male-to-female ratio of 3:2. The 
median SAPS-II score at T-ASTmax was 66.0 (Q1–Q3 
Fig. 2 Survival curves by cause of hypoxic hepatitis. T-ASTmax is designated as the time 0. T-ASTmax time point of maximum AST value
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43.0–81.0). 74.9% of patients required mechanical ven-
tilation. Vasopressor and inotropic agents were used in 
60.8 and 43.2%, respectively, and 9.5% were on dialysis 
at T-ASTmax. The causes of HH, in decreasing order 
of frequency, were  cardiac failure (49.1%), septic shock 
(29.8%), hypovolemic shock (9.4%), acute respiratory fail-
ure (6.4%), acute on chronic respiratory failure (3.3%), 
pulmonary embolism (1.4%) and hyperthermia (0.5%). 
An episode of HH (length of time that AST levels are 
exceeding 5 times the ULN) had a median duration of 
54.3 (Q1–Q3 26.4–94.2)  h, during which the median 
recovery time (duration from peak AST to levels below 5 
times the ULN) was 34.7 (Q1–Q3 14.6–67.2) h.
Survivors had significantly lower severity of illness 
scores (median SAPS-II score of 54.0 vs. 76.0, P < 0.001 
and median APS-II score 25.0 vs. 30.0, P  =  0.005) as 
compared to non-survivors. They were less likely to have 
septic shock (25.6 vs. 35.1%, P = 0.003). Peak AST levels 
above 20 times ULN were less commonly seen in survi-
vors (33.4 vs. 50.8%, P  <  0.001). More characteristics, 
classified according to survival status, are presented in 
Table 1. 
The three ASTmax subgroups (“5–10× ULN” vs. “10–
20× ULN” vs. “>  20× ULN”) were also compared with 
each other. The causes of HH were equally represented 
within each subgroup. Patients with higher peak AST 
levels had higher severity of illness scores (median SAPS-
II score of 57.0 vs. 60.0 vs. 73.0, P < 0.001; median APS-
II score of 24.0 vs. 26.5 vs. 32.0, P < 0.001) and a higher 
need for supportive therapy, such as inotropic agents 
(38.5 vs. 37.9 vs. 50.2%, P  <  0.001), vasopressor agents 
(50.9 vs. 59.4 vs. 70.0%, P  <  0.001), dialysis (4.8 vs. 8.4 
vs. 14.1%, P < 0.001) and IABP (13.7 vs. 20.7% vs. 18.9%, 
P  =  0.041). In addition, higher peak AST levels were 
associated with higher 28-day mortality rates (33.2 vs. 
44.4 vs. 55.4%, P < 0.001). More characteristics, classified 
according to severity of HH and to cause of HH, are pre-
sented in Tables 2 and 3, respectively.
Trend of liver tests
The time trend of the liver tests is illustrated in Fig.  3. 
Once the AST level exceeded 5 times the ULN (desig-
nated as start of HH), it reached a median peak level of 
521.2 (Q1–Q3 269.1–1581.6) U/L within a median of 
16.3 (Q1–Q3 7.9–26.8)  h. Subsequently, AST started to 
decline, dropping below 5 times the ULN after a median 
time of 34.7 (Q1–Q3 14.6–67.2) h and normalizing after 
a median time of 6.4 (Q1–Q3 3.9–10.9) days in survivors.
ALT and LDH peaked at median values of 332.0 
(Q1–Q3 149.4–953.6)   U/L and 1180.6 (Q1–Q3 684.1–
2770.8) U/L within a median time of 22.0 (Q1–Q3 9.7–
43.0) and 21.4 (Q1–Q3 10.0–43.6)  h after start of HH, 
respectively. In survivors, LDH returned to baseline 
(<  233 U/L) within a median of 5.1 (Q1–Q3 1.3–15.9) 
days after its peak. ALT declined more slowly, return-
ing to baseline (< 31 and < 40 U/L for females and males, 
respectively) within 8.6 (Q1–Q3 3.9–16.5) days after its 
peak. When considering all patients, including those with 
AST already exceeding 5 times the ULN at ICU admis-
sion, ALT and LDH peaked at T-ASTmax in the majority 
of patients (65.5 and 53.1%, respectively) and to a lesser 
extent after T-ASTmax (26.2 and 29.8%, respectively).
The median relative increase of AST, ALT and LDH at 
T-ASTmax was 15.0, 8.7 and 4.7 times their ULN, respec-
tively. LDH exceeded both AST and ALT at all time 
points in more than 80% of patients. The median AST/
ALT ratio was 1.6 at the start of HH, increased to 1.8 at 
T-ASTmax and subsequently declined, reversing within a 
median of 32.5 h after T-ASTmax.
In addition, Fig. 3 illustrates that the median INR, cre-
atinine and bilirubin levels also peaked at T-ASTmax, 
albeit to a much less extent, with median bilirubin level 
never exceeding the ULN. This is also illustrated in Fig. 4. 
Both in survivors and non-survivors, the proportion of 
patients with bilirubin level above the ULN increased 
mildly at T-ASTmax and then gradually decreased again. 
The proportion of survivors with bilirubin above 3 times 
the ULN was limited and increased slightly later dur-
ing ICU stay. Likewise, AP remained stable during HH, 
except for a mild increase later during ICU stay, as illus-
trated in Figs. 3 and 4.
The pattern of liver enzyme alterations described above 
was found in all ASTmax subgroups (see Appendix 
Figs.  5, 6, 7). Median values of other laboratory tests at 
start of HH and at T-ASTmax are presented in Table 4.
28‑day mortality
HH was associated with high mortality rates, especially 
early in its course. 18.5% died within 24 h after T-AST-
max. After this first day, the hazard declined dramati-
cally, but remained quite high, resulting in 40.2 and 45.0% 
all-cause mortality at 14 and 28 days, respectively. 90.6% 
of deaths occurred during ICU stay.
Twenty-eight-day mortality rates differed significantly 
among the causes of HH (P = 0.007). The high number 
of early deaths in the pulmonary embolism, septic shock 
and hypovolemic shock subgroups mainly accounted for 
the early mortality associated with HH. 37.5, 24.3, 25.7% 
of these patients died within 24 h after T-ASTmax. The 
mortality rate in the pulmonary embolism subgroup 
exceeded at all times those of other subgroups and ulti-
mately resulted in 56.2% mortality at 28 days. The septic 
shock and hypovolemic shock subgroups had a 28-day 
mortality of 52.9 and 43.8%, respectively. While the early 
mortality in the cardiac failure subgroup was less pro-
nounced, yet still considerable as 14.8% of these patients 
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died within 24  h, its 28-day mortality of 41.4% ranked 
fourth among all subgroups. The acute respiratory failure 
and acute on chronic respiratory failure subgroups had 
similar survival curves and outcome, with 39.4 and 37.8% 
mortality at 28 days. The lowest mortality rate of 33.3% at 
28 days was observed in the hyperthermia subgroup. The 
survival curves by cause of HH are presented in Fig. 2.
The 28-day mortality also increased significantly 
(P  <  0.001) with severity of HH, ranging from 33.2% in 
the “5–10× ULN” subgroup to 55.4% in the “> 20× ULN” 
Table 3 Characteristics of patients with HH classified by clinical cause
Variable Cause
Cardiac failure 
(n = 548)
Septic shock 
(n = 333)
Hypov‑
olemic shock 
(n = 105)
Acute res‑
piratory failure 
(n = 71)
Acute 
on chronic res‑
piratory failure 
(n = 37)
Pulmonary 
embolism 
(n = 16)
Hyperthermia 
(n = 6)
P
Sexa
 Male 63.1% (346) 61.6 (205) 57.1% (60) 54.9% (39) 54.1% (20) 62.5 (10) 66.7% (4) 0.721
Ageb (year) 68.0 (58.0–76.0) 64.0 (52.0–74.0) 64.0 (56.0–73.0) 59.0 (48.5–71.5) 65.0 (61.0–72.0) 57.5 (47.5–61.5) 54.5 (35.8–64.2) 0.003
BMIb (kg/m2) 25.5 (23.3–28.7) 25.0 (22.1–29.3) 26.2 (23.4–28.9) 24.2 (22.0–27.8) 24.6 (22.1–27.3) 27.8 (25.1–31.0) 27.6 (23.7–29.3) 0.202
Comorbidities
 Echocardioa
  Normal 32.7% (179) 51.1% (170) 43.8% (46) 36.6% (26) 48.6% (18) 18.8% (3) 66.7% (4) < 0.001
  LV dysf. 36.5% (200) 15.9% (53) 5.7% (6) 21.1% (15) 10.8% (4) 6.2% (1) 16.7% (1) < 0.001
  Missing 13.3% (73) 26.1% (87) 46.7% (49) 35.2% (25) 24.3% (9) 25.0% (4) 16.7% (1) < 0.001
  LV and RV 
dysf.
13.0% (71) 3.3% (11) 1.0% (1) 4.2% (3) 2.7% (1) 12.5% (2) 0.0% (0) < 0.001
  RV dysf. 4.6% (25) 3.6% (12) 2.9% (3) 2.8% (2) 13.5% (5) 37.5% (6) 0.0% (0 < 0.001
 DMa 20.8% (114) 19.2% (64) 10.5% (11) 12.7% (9) 24.3% (9) 12.5% (2) 0.0% (0) 0.103
 Chronic 
respiratory 
 failurea
8.4% (46) 9.6% (32) 9.5% (10) 0.0% (%) 100.0% (37) 12.5% (2) 0.0% (0) < 0.001
SOI  scoresc
 APS-IIb 28.0 (23.0–35.0) 26.0 (21.0–35.0) 26.0 (18.5–32.5) 30.0 (28.0–34.0) 26.5 (24.2–30.8) 36.5 (36.2–36.8) 21.5 (19.2–25.0) 0.590
 SAPS-IIb 66.0 (44.0–79.0) 67.0 (49.0–84.0) 65.0 (48.0–82.0) 63.0 (31.0–79.0) 67.5 (55.0–73.5) 83.0 (69.2–99.2) 41.5 (34.0–48.2) 0.171
ASTmaxa
 Overall 0.135
 5–10× ULN 36.5% (200) 34.8% (116) 28.6% (30) 39.4% (28) 35.1% (13) 37.5% (6) 33.3% (2) –
 10–20× ULN 23.7% (130) 20.4% (68) 25.7% (27) 33.8% (24) 13.5% (5) 25.0% (4) 50.0% (3) –
 > 20× ULN 39.8% (218) 44.7% (149) 45.7% (48) 26.8% (19) 51.4% (19) 37.5% (6) 16.7% (1) –
Supportive 
 therapyc
 Ventilationa 79.2% (434) 73.0% (243) 70.5% (74) 60.6% (43) 64.9 (24) 75.0% (12) 100.0% (6) 0.004
 Medication
  Inotropic 
 agentsa
63.1% (346) 26.4% (88) 21.0% (22) 12.7% (9) 21.6% (8) 43.8% (7) 33.3% (2) < 0.001
  Vasopressor 
 agentsa
58.6% (321) 69.1% (230)d 61.9% (65) 46.5% (33) 43.2% (16) 75.0% (12) 16.7% (1) < 0.001
 Dialysisa 10.4% (57) 11.1% (37) 2.9% (3) 9.9% (7) 2.7% (1) 0.0% (0) 16.7% (1) 0.090
 IABPa 32.8% (180) 4.2% (14) 0.0% (0) 1.4% (1) 0.0% (0) 0.0% (0) 0.0% (0) < 0.001
LOS
 ICUb (day) 4.6 (1.4–10.5) 4.7 (0.9–15.8) 2.6 (0.7–7.8) 6.3 (2.3–15.0) 3.2 (1.4–7.8) 2.2 (0.3–4.1) 7.7 (6.6–14.2) 0.135
 Hospitalb (day) 11.1 (4.6–25.7) 12.3 (1.1–37.9) 11.2 (0.9–28.8) 14.3 (5.2–30.2) 20.6 (7.6–27.7) 5.4 (0.3–19.4) 43.4 (10.2–97.4) 0.037
Duration
 Episode of 
 HHb (h)
50.6 (24.9–99.3) 54.5 (25.1–87.2) 69.4 (36.8–89.5) 71.3 (39.0–90.0) 28.4 (15.1–77.2) 69.5 (28.0–
139.0)
54.6 (35.4–74.0) 0.137
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subgroup. There was no significant difference (P = 0.363) 
in 28-day mortality between men (39.8%) and women 
(42.4%).
Discussion
Hypoxic hepatitis is a type of acute hepatic injury in criti-
cally ill patients caused by cardiac, circulatory or respira-
tory failure. While commonly known and referred to 
as “shock liver” in daily clinical practice, little research 
has been done. However, early recognition of HH and 
management of its underlying cause and complications 
may improve ultimate outcome. For a long time, only 
studies with a relatively small number of patients have 
been conducted. In 2015, a meta-analysis of 24 stud-
ies that included 1782 patients summarized the avail-
able evidence, but still lacked detailed information on 
important patient characteristics, biochemical findings 
and clinical course [2]. To overcome these shortcomings, 
Aboelsoud et al. recently performed an extensive analy-
sis of the Medical Information Mart for Intensive Care III 
Table 3 continued
Variable Cause
Cardiac failure 
(n = 548)
Septic shock 
(n = 333)
Hypov‑
olemic shock 
(n = 105)
Acute res‑
piratory failure 
(n = 71)
Acute 
on chronic res‑
piratory failure 
(n = 37)
Pulmonary 
embolism 
(n = 16)
Hyperthermia 
(n = 6)
P
 Recovery of 
 HHb (h)
33.8 (3.4–67.5) 34.3 (14.3–60.9) 41.7 (21.1–65.1) 31.0 (16.2–62.1) 39.9 (11.6–89.3) 35.3 (10.5–65.4) 29.6 (21.7–43.3) 0.810
28-day mortality
 ICUa 37.8% (207) 48.3% (161) 40.0% (42) 33.8% (24) 27.0% (10) 56.2% (9) 33.3% (2) 0.012
 In-hospitala 41.4% (227) 52.9% (176) 43.8% (46) 39.4% (28) 37.8% (14) 56.2% (9) 33.3% (2) 0.029
APS-II acute physiology II, AST aspartate aminotransferase, ASTmax maximum AST value, BMI body mass index, HH hypoxic hepatitis, IABP intra-aortic balloon pump, 
ICU intensive care unit, LOS length of stay, LV left ventricle, P P value, Q1 first quartile, Q3 third quartile, RV right ventricle, SAPS-II simplified acute physiology II, SOI 
severity of illness, T-ASTmax time point of maximum AST value, ULN upper limit of normal
a % (n)
b Median (Q1–Q3)
c At T-ASTmax ± 12 h
d A condition for septic shock was the need of vasopressor agents. In this table, the proportion of patients receiving vasopressor agents only at T-ASTmax is given
Fig. 3 Time trend of liver tests in hypoxic hepatitis. Time trend of the median AP, ALT, AST, bilirubin, creatinine, INR and LDH levels in hypoxic hepa-
titis. T-ASTmax is designated as time 0. AST, ALT, LDH and AP levels are measured in U/L and are plotted using the left y-axis. Bilirubin and creatinine 
levels are measured in mg/dL and plotted using the right y-axis. INR has no unit, but is also plotted using the right y-axis. AP alkaline phosphatase, 
ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio, LDH lactate dehydrogenase
Page 10 of 13Van den broecke et al. Ann. Intensive Care  (2018) 8:15 
(MIMIC-III) research database. Their study comprised 
565 patients with HH and was the largest cohort study 
published to date [8].
In our study of 1116 critically ill patients with HH, we 
investigated in detail its incidence, causes, evolution and 
outcome. We used an AST cutoff of at least 5 times the 
ULN (i.e., 155 and 185 U/L for females and males, respec-
tively) to define HH, while other studies have used higher 
cutoff values ranging from 400 to 3000 U/L [2]. HH has 
been histologically proven to occur even in patients with 
moderately elevated AST levels (at AST levels of 252 and 
300  IU/L in the cohort of Cohen et  al. [13] and Bynum 
et  al. [14], respectively). Additionally, by using a lower 
cutoff, the sensitivity to identify patients with HH could 
be increased. However, this approach could also result 
in a lower specificity, leading to an increased number 
of patients that are falsely diagnosed as having HH. In 
order to maintain a high specificity, we have thoroughly 
reviewed the clinical notes, the time trend of liver tests 
and the discharge summaries of the 4012 identified 
Fig. 5 Time trend of liver tests in hypoxic hepatitis of the ASTmax subgroup 5-10x ULN. Time trend of the median AP, ALT, AST, bilirubin, creatinine, 
INR and LDH levels in hypoxic hepatitis. T-ASTmax is designated as time 0. AST, ALT, LDH and AP levels are measured in U/L and are plotted using 
the left y-axis. Bilirubin and creatinine levels are measured in mg/dL and plotted using the right y-axis. INR has no unit, but is also plotted using the 
right y-axis. AP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio, LDH lactate 
dehydrogenase
Fig. 4 a AP level range over time; b bilirubin level range over time. Evolution of the proportion of survivors and non-survivors with alkaline phos-
phatase (left) and bilirubin (right) levels within and outside the reference range. T-ASTmax is designated as time 0. AP alkaline phosphatase, LLN 
lower limit of normal, ULN upper limit of normal
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patients whose AST level exceeded our cutoff value. Our 
high number of excluded patients (70.0%) after applying 
extensive exclusion criteria may reflect a high specific-
ity. In contrast, Aboelsoud et al. [8] used a cutoff of 800 
U/L for both AST and ALT to include patients, but only 
excluded 24.3% of these patients based on evidence of 
acetaminophen poisoning, acute viral hepatitis or liver 
surgery.
Our study uncovered interesting results. Firstly, it 
indicated that HH may be more common than previ-
ously thought. In our study, an incidence of 4.0% was 
observed, which is higher than the pooled incidence of 
2.5% from a meta-analysis of 1782 patients [2] and the 
incidence of 1.5% in the MIMIC-III cohort [8]. Moreo-
ver, approximately one in five critically ill patients that 
have died during their ICU stay had developed HH. This 
Fig. 6 Time trend of liver tests in hypoxic hepatitis of the ASTmax subgroup 10-20x ULN. Time trend of the median AP, ALT, AST, bilirubin, creatinine, 
INR and LDH levels in hypoxic hepatitis. T-ASTmax is designated as time 0. AST, ALT, LDH and AP levels are measured in U/L and are plotted using 
the left y-axis. Bilirubin and creatinine levels are measured in mg/dL and plotted using the right y-axis. INR has no unit, but is also plotted using the 
right y-axis. AP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio, LDH lactate 
dehydrogenase
Fig. 7 Time trend of liver tests in hypoxic hepatitis of the ASTmax subgroup >20x ULN. Time trend of the median AP, ALT, AST, bilirubin, creatinine, 
INR and LDH levels in hypoxic hepatitis. T-ASTmax is designated as time 0. AST, ALT, LDH and AP levels are measured in U/L and are plotted using 
the left y-axis. Bilirubin and creatinine levels are measured in mg/dL and plotted using the right y-axis. INR has no unit, but is also plotted using the 
right y-axis. AP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio, LDH lactate 
dehydrogenase
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higher incidence observed in our study is of course a 
direct consequence of the lower AST cutoff used. How-
ever, it should be noted that the underlying conditions, 
the typical liver test pattern and the considerable mortal-
ity of 33.2% at 28 days in patients with a less pronounced 
rise of AST (peak AST level between 5 and 10 times the 
ULN) are just as much compatible with the diagnosis of 
HH as in patients with higher peak AST level. Any sud-
den increase in aminotransferases above 5 times the ULN 
should therefore prompt the clinician to actively search 
for any changes in physiological parameters and maintain 
strict hemodynamic and respiratory control.
Secondly, the typical liver test pattern that suggests 
diagnosis of HH was observed in all subgroups of our 
study cohort. HH was characterized by (1) a sudden and 
significant increase of aminotransferases with an AST/
ALT ratio greater than 1, (2) a similar rise in LDH mostly 
exceeding both AST and ALT and (3) a steady decline of 
aminotransferases with reversal of the AST/ALT ratio 
approximately 1.5  days after T-ASTmax. In survivors, 
LDH normalized first, followed by AST and finally ALT 
(median of 5.1, 6.4 and 8.6 days after T-ASTmax, respec-
tively). Bilirubin followed a similar pattern as the ami-
notransferases, but the magnitude of its increase was 
much less pronounced, with median levels never exceed-
ing the ULN. The associated prolongation of INR and 
impairment of renal function as described by Raurich 
et al. [6] were also confirmed in this study.
Finally, we observed a 28-day mortality of 45.0%, 
which is in line with the reported mortality of 49% from 
a meta-analysis of 1782 patients [2] and the mortality of 
44.1% in the MIMIC-III cohort [8]. HH was especially 
associated with high mortality rates early in its course, 
with roughly 40% of deaths occurring within 24  h after 
T-ASTmax. This was mainly driven by the severity of 
the underlying causes [2], although the ultimate cause 
of death was not inferred in this study. The magnitude of 
AST increase also appeared to be correlated with mortal-
ity on univariate analysis.
Our study has a number of strengths. To our knowl-
edge, it is by far the largest cohort study of patients with 
HH (n =  1116). It comprises twice as many patients as 
the second largest cohort study, which was recently pub-
lished and included 565 patients [8]. Additionally, by 
using a low AST cutoff of 5 times the ULN while simul-
taneously excluding many conditions that could mimic 
HH, we are confident that we could identify nearly all 
patients with HH at our center with a low risk of mis-
diagnosis. Our study may have some limitations inher-
ent in its retrospective design. However, we believe that 
the retrospective design had little to no impact on our 
results given the entirely computerized monitoring and 
management at our ICU, the detailed review of patient 
records and the high number of patients included. Nev-
ertheless, we should be careful to generalize these results 
to a broader patient population since only critically ill 
patients older than 18 years and only from a single uni-
versity hospital ICU were included.
Conclusions
This study surpasses by far the largest cohort of criti-
cally ill patients with hypoxic hepatitis. HH is more com-
mon than previously thought with an ICU incidence of 
4.0%, and it is associated with a high all-cause mortality 
of 45.0% at 28 days. The main causes of HH are cardiac 
failure and septic shock, which include more than 3/4 
of all episodes. Clinicians should search actively for any 
underlying hemodynamic or respiratory instability even 
in patients with moderately increased AST levels.
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